Diverse Biotech Announces New Patent Approval for Its PEMBROLIZUMAB Antibody Drug DBT-50201
MIAMI–(BUSINESS WIRE)– #CBD–Diverse Biotech has been granted USPTO patent approval of its novel CUSP synthesis platform creating an entirely new class of drugs that are part-antibody and part-cannabinoid in one new molecule. Starting with DBT-50201, its novel PEMBROLIZUMAB compound, Diverse expects to develop multiple treatments for many diseases with highly ... Read More